9th Annual Gene Therapy Development Summit

9th Annual Gene Therapy Development Summit is organized by Hanson Wade and will be held from Mar 24 - 26, 2026 at Revere Hotel Boston Common, Boston, Massachusetts, United States of America.

Description:
Gene therapy is entering a defining new chapter. After a period of challenge and recalibration, the field is regaining momentum, driven by teams who remain steadfast in their belief that this science can transform lives. Confidence is returning, with significant investments and acquisitions signalling a renewed commitment to overcoming barriers of safety, efficacy, and scalability.

The 9th Gene Therapy Development Summit returns to Boston as the meeting point for this community. Join 100+ leading voices from the likes of Bayer, Astellas Pharmaceuticals, REGENXBIO, Ocugen, AskBio, CureDuchenne Ventures, and more to come together to share ideas, restore confidence, and chart a sustainable path forward for gene therapy.

Connect with your peers in pre-clinical development, manufacturing, analytical development, clinical operations, and regulatory affairs for an unrivalled learning and networking opportunity across the end-to-end of gene therapy development.

3 Reasons to Attend:

• DISCOVER first-hand insights into how nextgeneration AAVs, smarter trial designs, and scalable manufacturing are driving safer, more accessible, and commercially viable gene therapies.
• BUILD your strategy by uncovering practical solutions for sustainable commercialization, robust analytics, and efficient development across both rare and common disease programs.
• ENGAGE with the global community committed to advancing gene therapy and form collaborations that drive lasting scientific and commercial progress.

Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Adrian Veres, Co-Founder and Chief Scientific Officer, Dyno Therapeutics, Alicia Gomez, MSW, Independent Social Work Coordinator, Independent Expert, Alison Niewiarowska, Head of Biological Products Medicine and Healthcare products, Regulatory Agency, Amber Salzman, Chief Executive Officer, Epicrispr Biotechnologies, Andrea Moore, Vice President - Analytical Development and Quality Control, Asklepios BioPharmaceutical, Inc. (AskBio), Andrew Steinsapir, Director and Gene Therapy Program Lead and Acting Chief Technology Officer, Deerfield Management and Apertura Gene Therapy, Casey Maguire, Associate Professor of Neurology, Harvard Medical School, Chrissy Burton, Senior Director - Clinical Operations, BridgeBio Pharma, Inc., Craig Malzahn, Senior Vice President, REGENXBIO, Damir Simic, Executive Director and Head of Integrative Science, Astellas Pharma, Derek Jackson, Senior Vice President - Product Development, Pacira Pharmaceuticals Inc, Devyn Smith, Chief Executive Officer, Arbo Bio, Hebe Sun, Associate Director, CDx/IVD Regulatory Affairs, Regeneron Pharmaceuticals, Jon Weber, Senior Director, Cell and Amp Gene Therapy Market Access Lead, Bayer, Jorge Santiago-Ortiz, Vice President - CMC and Regulatory Affairs, Apertura Gene Therapy, Karsten Peppel, Associate Director - Gene Therapy, CSL, Lianna Orlando, Vice President - Research and Partner, CureDuchenne, Lindsay Marjoram, Director of Research, Barth Syndrome Foundation Inc, Lorelei Stoica, Executive Director, of Non-Clinical Research, Ultragenyx Pharmaceutical Inc., Mehrnaz sheibani, Postdoctoral, UT Southwestern Medical Center, Melis McHenry, Associate Director, Regeneron Pharmaceuticals, Mitra Tavakkoli, Executive Medical Lead, BridgeBio Pharma, Inc., Pushpendra Singh, Senior Director, Head of Product Development, Ocugen, Rajeev Boregowda, Associate Director, Bioassay and Molecular Analytical Development, Genomic Medicine CMC, Sanofi, Ralf Schmid, Independent Expert, Independent Expert, Roelof Rongen, Chief Executive Officer Adolore, BioTherapeutics, Stephen Poor, Head of Translational Medicine, Apellis Pharmaceuticals, Tassos Georgiadis, Senior Vice President Discovery and Preclinical Development, MeiraGTx, Thomas Dee, CEO, Endsulin, TJ Cradick, Chief Scientific Officer, Gene Editing Frontiers, William Pu, Director of Basic and Translational Research, Department of Cardiology, Boston Children’s Hospital; Aldo R. Casteñeda Professor, Harvard Medical School and Boston Children's Hospital